Mitsutaka Nishimoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mitsutaka Nishimoto has a total of 139 co-authors. Here are the top co-authors by number of shared publications:
- Hirohisa Nakamae
Department of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan
11 shared publications Masayuki Hino
Department of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, 545-8585, Japan
10 shared publications- Yasuhiro Nakashima
Hematology and Hematopoietic Cell Transplantation, Osaka Metropolitan University Hospital, Osaka, Japan
10 shared publications Hideo Koh
Department of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan
7 shared publicationsHiroshi Okamura
Department of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, 545-8585, Japan
7 shared publications- Hiroshi Okamura
Department of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan
7 shared publications
Latest Publications
- 29 March 2026
- Published by Springer Nature in International Journal of Hematology
- Vol. 124 (2) , 283-294
Phase-specific impact of hypogammaglobulinemia on bacterial infections after allogeneic hematopoietic cell transplantation
Infections are a major complication after allogeneic hematopoietic cell transplantation (allo-HCT). Although humoral immunity is essential, the phase-specific role of IgG remains unclear. We analyzed 579 allo-HCT recipients, stratified into early, intermediate, and late post-transplant phases. The incidence of bacterial infections during the intermediate phase decreased with increasing IgG trough levels (incidence rate ratio [IRR], 0.85; 95% confidence interval [CI]: 0.78-0.94, p < 0.01), whereas no association was observed in the early or late phases. During the intermediate phase, multivariable analyses demonstrated that hypogammaglobulinemia (IRR, 1.70; 95% CI: 1.11-2.62, p = 0.02) and acute graft-versus-host disease with grade II-IV (IRR, 2.10; 95% CI: 1.39-3.18, p < 0.01) were associated with bacterial infections. In models including high-dose steroid exposure, steroid therapy was independently associated with bacterial infections, whereas the effect of hypogammaglobulinemia was attenuated. There was a trend toward an interaction between hypogammaglobulinemia and high-dose steroid exposure. A stratified analysis suggested that hypogammaglobulinemia had a more pronounced impact among patients without high-dose steroids (IRR 1.86; 95% CI: 1.09-3.16; p = 0.02). These findings suggest the clinical relevance of hypogammaglobulinemia is phase-specific and influenced by the intensity of immunosuppressive therapy. Monitoring IgG during this period may help identify candidates for targeted immunoglobulin replacement therapy.
- 29 March 2026
- Published by Springer Nature in International Journal of Hematology
- Vol. 124 (2) , 283-294
Phase-specific impact of hypogammaglobulinemia on bacterial infections after allogeneic hematopoietic cell transplantation
Infections are a major complication after allogeneic hematopoietic cell transplantation (allo-HCT). Although humoral immunity is essential, the phase-specific role of IgG remains unclear. We analyzed 579 allo-HCT recipients, stratified into early, intermediate, and late post-transplant phases. The incidence of bacterial infections during the intermediate phase decreased with increasing IgG trough levels (incidence rate ratio [IRR], 0.85; 95% confidence interval [CI]: 0.78-0.94, p < 0.01), whereas no association was observed in the early or late phases. During the intermediate phase, multivariable analyses demonstrated that hypogammaglobulinemia (IRR, 1.70; 95% CI: 1.11-2.62, p = 0.02) and acute graft-versus-host disease with grade II-IV (IRR, 2.10; 95% CI: 1.39-3.18, p < 0.01) were associated with bacterial infections. In models including high-dose steroid exposure, steroid therapy was independently associated with bacterial infections, whereas the effect of hypogammaglobulinemia was attenuated. There was a trend toward an interaction between hypogammaglobulinemia and high-dose steroid exposure. A stratified analysis suggested that hypogammaglobulinemia had a more pronounced impact among patients without high-dose steroids (IRR 1.86; 95% CI: 1.09-3.16; p = 0.02). These findings suggest the clinical relevance of hypogammaglobulinemia is phase-specific and influenced by the intensity of immunosuppressive therapy. Monitoring IgG during this period may help identify candidates for targeted immunoglobulin replacement therapy.
- Open Access
- 10 March 2026
- Published by Wiley in Transplant Infectious Disease
- Vol. 28 (3) , e70194
Effects of Various Immunoglobulin Products on Serum (1‐3)‐β‐D‐glucan Levels
Background: (1‐3)‐β‐D‐glucan (β‐D‐glucan), a component of fungal cell walls and an important diagnostic biomarker of invasive fungal infections, is affected by various factors, particularly in allogeneic hematopoietic cell transplantation (allo‐HCT) recipients. Patients receiving allo‐HCT also receive immunoglobulin replacement therapy (IgRT); however, little is known about the effects of different types of immunoglobulin products on serum β‐D‐glucans. Here, we examined the levels of serum β‐D‐glucan following IgRT, as well as the correlation between changes in serum β‐D‐glucan and IgG levels. Methods: Serum β‐D‐glucan levels in patients who underwent allo‐HCT and IgRT at our institution between 2021 and 2024 were analyzed retrospectively. Patients who had their serum β‐D‐glucan measured within 7 days before and after IgRT were included, and changes in serum β‐D‐glucan levels were evaluated across product types. Finally, the magnitude of these changes was assessed using effect sizes. Results: A total of 125 administrations of three types of immunoglobulin product (Privegen [ n = 63], Venoglobulin [ n = 38], and Venilon‐I [ n = 24]) were examined. The median dose of immunoglobulin was 538.9 (57.4–700.9) mg/kg. We noted a significant increase in serum β‐D‐glucan levels after administration of Privigen, with a large effect size (Cohen's dz = 0.92; 95% confidence interval 0.48–1.35, p < 0.01). No meaningful changes were detected with Venoglobulin or Venilon‐I. Elevated serum β‐D‐glucan levels returned to baseline within approximately 3 weeks of Privigen administration. Multivariable analysis indicated that Privigen was an independent factor associated with higher serum β‐D‐glucan levels. Conclusion: Different immunoglobulin products have different effects on serum β‐D‐glucan levels after IgRT. image
- 10 March 2026
- Published by Wiley in Transplant Infectious Disease
- Vol. 28 (3) , e70194
Open AccessEffects of Various Immunoglobulin Products on Serum (1‐3)‐β‐D‐glucan Levels
Background: (1‐3)‐β‐D‐glucan (β‐D‐glucan), a component of fungal cell walls and an important diagnostic biomarker of invasive fungal infections, is affected by various factors, particularly in allogeneic hematopoietic cell transplantation (allo‐HCT) recipients. Patients receiving allo‐HCT also receive immunoglobulin replacement therapy (IgRT); however, little is known about the effects of different types of immunoglobulin products on serum β‐D‐glucans. Here, we examined the levels of serum β‐D‐glucan following IgRT, as well as the correlation between changes in serum β‐D‐glucan and IgG levels. Methods: Serum β‐D‐glucan levels in patients who underwent allo‐HCT and IgRT at our institution between 2021 and 2024 were analyzed retrospectively. Patients who had their serum β‐D‐glucan measured within 7 days before and after IgRT were included, and changes in serum β‐D‐glucan levels were evaluated across product types. Finally, the magnitude of these changes was assessed using effect sizes. Results: A total of 125 administrations of three types of immunoglobulin product (Privegen [ n = 63], Venoglobulin [ n = 38], and Venilon‐I [ n = 24]) were examined. The median dose of immunoglobulin was 538.9 (57.4–700.9) mg/kg. We noted a significant increase in serum β‐D‐glucan levels after administration of Privigen, with a large effect size (Cohen's dz = 0.92; 95% confidence interval 0.48–1.35, p < 0.01). No meaningful changes were detected with Venoglobulin or Venilon‐I. Elevated serum β‐D‐glucan levels returned to baseline within approximately 3 weeks of Privigen administration. Multivariable analysis indicated that Privigen was an independent factor associated with higher serum β‐D‐glucan levels. Conclusion: Different immunoglobulin products have different effects on serum β‐D‐glucan levels after IgRT. image
- Open Access
- 8 May 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (7) , 1627-1639
Regulation of H3K4me3 breadth and MYC expression by the SETD1B catalytic domain in MLL-rearranged leukemia
Histone H3 lysine 4 trimethylation (H3K4me3) is abundant in mixed-lineage leukemia-rearranged (MLL-r) acute myeloid leukemia (AML) cells; however, the responsible enzymes and their roles remain unclear. This study aimed to identify the modifier responsible for high H3K4me3 modification in MLL-r leukemia and its downstream targets essential for the cell proliferation. Here, we performed a CRISPR-tiling screen against known H3K4 methylation modifiers in an MLL-r AML model. Disrupting the SETD1B catalytic SET domain caused depletion of FLT3-ITD or NrasG12D-expressing AML cells, and gene expression downregulation, particularly in the MYC pathway. SETD1B SET domain loss results in a significant decrease in H3K4me3 breadth. Exogenous MYC expression or disrupting H3K4 demethylase KDM5C significantly restored growth defects in SETD1B SET domain-mutant cells. These data indicated that SETD1B was required for H3K4me3 breadth and MYC expression. Thus, a thorough understanding of SETD1B-mediated H3K4me3 breadth is critical for developing markers and therapies for MYC-dependent leukemia subtypes.
- 8 May 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (7) , 1627-1639
Open AccessRegulation of H3K4me3 breadth and MYC expression by the SETD1B catalytic domain in MLL-rearranged leukemia
Histone H3 lysine 4 trimethylation (H3K4me3) is abundant in mixed-lineage leukemia-rearranged (MLL-r) acute myeloid leukemia (AML) cells; however, the responsible enzymes and their roles remain unclear. This study aimed to identify the modifier responsible for high H3K4me3 modification in MLL-r leukemia and its downstream targets essential for the cell proliferation. Here, we performed a CRISPR-tiling screen against known H3K4 methylation modifiers in an MLL-r AML model. Disrupting the SETD1B catalytic SET domain caused depletion of FLT3-ITD or NrasG12D-expressing AML cells, and gene expression downregulation, particularly in the MYC pathway. SETD1B SET domain loss results in a significant decrease in H3K4me3 breadth. Exogenous MYC expression or disrupting H3K4 demethylase KDM5C significantly restored growth defects in SETD1B SET domain-mutant cells. These data indicated that SETD1B was required for H3K4me3 breadth and MYC expression. Thus, a thorough understanding of SETD1B-mediated H3K4me3 breadth is critical for developing markers and therapies for MYC-dependent leukemia subtypes.
- 22 October 2024
- Published by Wiley in British Journal of Haematology
- Vol. 205 (6) , 2376-2386
Comparison of HLA ‐haploidentical donors with post‐transplant cyclophosphamide versus HLA ‐matched unrelated donors in peripheral blood stem cell transplantation for acute myeloid leukaemia
Summary: HLA‐haploidentical haematopoietic cell transplantation with post‐transplant cyclophosphamide (PTCy‐haplo) is emerging as an effective alternative due to donor availability and safety. We conducted a nationwide retrospective study comparing the outcomes of PTCy‐haplo with both anti‐thymocyte globulin (ATG)‐free and ATG‐administered matched unrelated donors (MUD) transplantation, using peripheral blood stem cells as the first transplantation for acute myeloid leukaemia (AML). Our study showed a lower and slower haematopoietic recovery and a higher incidence of infection‐related deaths after PTCy‐haplo than after MUD transplantation. In addition, we revealed an increased risk of acute and chronic graft‐versus‐host disease (GVHD) in ATG‐free MUD transplantation in comparison to PTCy‐haplo. For grades III–IV acute GVHD, the hazard ratio (HR) was 2.71 (95% CI, 1.46–5.01), and for extensive chronic GVHD, the HR was 3.11 (95% CI, 2.07–4.68). There was no significant difference regarding overall survival amongst the groups. In addition, GVHD‐free relapse‐free survival (GRFS) was lower in ATG‐free MUD transplantation than in PTCy‐haplo (HR, 1.46; 95% CI, 1.17–1.82). Notably, ATG‐administered MUD transplantation showed no significant difference in GRFS from PTCy‐haplo, negating the advantage of PTCy. Our results suggest that PTCy‐haplo could be viable for AML patients without an HLA‐matched related donor.
- 22 October 2024
- Published by Wiley in British Journal of Haematology
- Vol. 205 (6) , 2376-2386
Comparison of HLA ‐haploidentical donors with post‐transplant cyclophosphamide versus HLA ‐matched unrelated donors in peripheral blood stem cell transplantation for acute myeloid leukaemia
Summary: HLA‐haploidentical haematopoietic cell transplantation with post‐transplant cyclophosphamide (PTCy‐haplo) is emerging as an effective alternative due to donor availability and safety. We conducted a nationwide retrospective study comparing the outcomes of PTCy‐haplo with both anti‐thymocyte globulin (ATG)‐free and ATG‐administered matched unrelated donors (MUD) transplantation, using peripheral blood stem cells as the first transplantation for acute myeloid leukaemia (AML). Our study showed a lower and slower haematopoietic recovery and a higher incidence of infection‐related deaths after PTCy‐haplo than after MUD transplantation. In addition, we revealed an increased risk of acute and chronic graft‐versus‐host disease (GVHD) in ATG‐free MUD transplantation in comparison to PTCy‐haplo. For grades III–IV acute GVHD, the hazard ratio (HR) was 2.71 (95% CI, 1.46–5.01), and for extensive chronic GVHD, the HR was 3.11 (95% CI, 2.07–4.68). There was no significant difference regarding overall survival amongst the groups. In addition, GVHD‐free relapse‐free survival (GRFS) was lower in ATG‐free MUD transplantation than in PTCy‐haplo (HR, 1.46; 95% CI, 1.17–1.82). Notably, ATG‐administered MUD transplantation showed no significant difference in GRFS from PTCy‐haplo, negating the advantage of PTCy. Our results suggest that PTCy‐haplo could be viable for AML patients without an HLA‐matched related donor.
- 26 August 2024
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 59 (11) , 1628-1630
Lower-dose post-transplant cyclophosphamide in haploidentical hematopoietic cell transplantation
- 26 August 2024
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 59 (11) , 1628-1630
Lower-dose post-transplant cyclophosphamide in haploidentical hematopoietic cell transplantation
- Open Access
- 14 May 2024
- Published by Springer Nature in Blood Cancer Journal
- Vol. 14 (1) , 1-5
T cells with high BCL-2 expression induced by venetoclax impact anti-leukemic immunity “graft-versus-leukemia effects”
- 14 May 2024
- Published by Springer Nature in Blood Cancer Journal
- Vol. 14 (1) , 1-5
Open AccessT cells with high BCL-2 expression induced by venetoclax impact anti-leukemic immunity “graft-versus-leukemia effects”
- 14 February 2024
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 59 (5) , 695-698
A comparison of long-term outcomes by donor type in the era of post-transplantation cyclophosphamide for aggressive adult T-cell leukemia/lymphoma
- 14 February 2024
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 59 (5) , 695-698
A comparison of long-term outcomes by donor type in the era of post-transplantation cyclophosphamide for aggressive adult T-cell leukemia/lymphoma
- Open Access
- 15 September 2023
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 62 (18) , 2737-2741
Ibrutinib Induces a Dramatic Improvement for Idiopathic Refractory Ascites Following Allogeneic Hematopoietic Cell Transplantation
We herein report a case of idiopathic refractory ascites following allogeneic hematopoietic cell transplantation that was successfully treated with ibrutinib. A 39-year-old man presented with massive transudative ascites. Despite a high portal venous pressure, the liver histology showed traces of alloreactivity inconsistent with veno-occlusive disease/sinusoidal obstructive syndrome. Ibrutinib was administered for ascites possibly secondary to portal hypertension associated with the alloreactivity. The ascites dramatically improved, and the portal venous pressure was reduced. This case may help clarify the mechanism through which refractory ascites develops after allogeneic hematopoietic cell transplantation and establish appropriate treatment protocols.
- 15 September 2023
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 62 (18) , 2737-2741
Open AccessIbrutinib Induces a Dramatic Improvement for Idiopathic Refractory Ascites Following Allogeneic Hematopoietic Cell Transplantation
We herein report a case of idiopathic refractory ascites following allogeneic hematopoietic cell transplantation that was successfully treated with ibrutinib. A 39-year-old man presented with massive transudative ascites. Despite a high portal venous pressure, the liver histology showed traces of alloreactivity inconsistent with veno-occlusive disease/sinusoidal obstructive syndrome. Ibrutinib was administered for ascites possibly secondary to portal hypertension associated with the alloreactivity. The ascites dramatically improved, and the portal venous pressure was reduced. This case may help clarify the mechanism through which refractory ascites develops after allogeneic hematopoietic cell transplantation and establish appropriate treatment protocols.